Advertisement
Advertisement

VERA

VERA logo

Vera Therapeutics, Inc. Class A Common Stock

33.38
USD
Sponsored
+2.11
+6.75%
Jun 04, 15:59 UTC -4
Closed
exchange

After-Market

34.26

+0.88
+2.64%

VERA Earnings Reports

Positive Surprise Ratio

VERA beat 6 of 21 last estimates.

29%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$1.63
Implied change from Q1 26 (Revenue/ EPS)
--
/
-3.55%
Implied change from Q2 25 (Revenue/ EPS)
--
/
+35.83%

Vera Therapeutics, Inc. Class A Common Stock earnings per share and revenue

On May 07, 2026, VERA reported earnings of -1.69 USD per share (EPS) for Q1 26, missing the estimate of -1.35 USD, resulting in a -24.86% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.95% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -1.63 USD, with revenue projected to reach -- USD, implying an decrease of -3.55% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Greenwich LifeSciences, Inc.
Report Date
Jun 01, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.57
Surprise
-77.70%
logo
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
FAQ
For Q1 2026, Vera Therapeutics, Inc. Class A Common Stock reported EPS of -$1.69, missing estimates by -24.86%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.95%, changed from $36.59 before the earnings release to $35.88 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 11 analysts, Vera Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$1.63 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement